FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer

Trial

DUO-E

Drug

Imfinzi (durvalumab) · Anti-PD-L1 antibody

Conditions

GynecologicOther solid neoplasm